Immunotherapy-induced vitiligo potentially corresponds to a cross-reaction against melanocyte differentiation antigens (MART-1, gp100, and tyrosinase-related proteins 1 and 2) shared by healthy and malignant melanocytes, and cytotoxic T lymphocytes are thought to be the main effector cells that recognize these shared antigens, which were found to infiltrate both tumor and vitiligo tissues [46,84]. Here, TYRP1 is linked to vitiligo.